Daiichi Sankyo Co Ltd
TSE:4568
Operating Margin
Daiichi Sankyo Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
Daiichi Sankyo Co Ltd
TSE:4568
|
6T JPY |
15%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
714.8B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
371.5B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
200.7B CHF |
32%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.7B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.5B USD |
36%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
114.6B EUR |
21%
|
Daiichi Sankyo Co Ltd
Glance View
Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth. The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Daiichi Sankyo Co Ltd's most recent financial statements, the company has Operating Margin of 14.8%.
You don't have any saved screeners yet